ODS vs Gummies: Dose Accuracy, Sugar, and Heat Stability

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs

Summary

A 2023 JAMA analysis of 25 US melatonin gummies found that 22 of them — 88 percent — were inaccurately labeled, with measured melatonin content ranging from 74 to 347 percent of the label claim (Cohen et al., 2023). The dose-accuracy problem is structural: gummy hot-fill manufacturing, mass-per-piece dosing, and matrix degradation make tight uniformity hard. Added sugar, heat instability, and a swallow-and-gut absorption route add further trade-offs. An oral dissolving strip (ODS) — a polymer film that dissolves against the buccal mucosa — sidesteps each of these. The MIHIYO Labs Sleep-Support ODS is engineered to deliver a precise, sugar-free, low-dose melatonin profile.

How does an oral dissolving strip compare with a gummy on dose accuracy?

The direct answer: independent laboratory testing has repeatedly found gummy supplements — especially melatonin gummies — to deviate substantially from their label claim, while a polymer-film oral dissolving strip (ODS) holds the active ingredient in a thin, uniform matrix that is cast and cut to a fixed area. In a 2023 JAMA Research Letter, Cohen et al. analyzed 25 melatonin gummy products and found 22 (88 percent) outside a ±10 percent label-claim window, with content spanning 74 to 347 percent of what the label claimed (JAMA, 2023, PMID 37097362). An earlier 2017 analysis of 30 commercial melatonin supplements found that over 71 percent did not meet label claim within a 10 percent margin, and 26 percent contained unlabeled serotonin (Erland & Saxena, J Clin Sleep Med, 2017, PMID 27855744).

This article walks through why gummies have this problem, what the published data show across four dimensions, and what an ODS does differently — without the rhetorical move of pretending gummies have no advantages. Palatability and adherence are real. Dose accuracy and stability are not.

Why gummy dose accuracy is hard

Gummies are confections first and dosage forms second. That order matters.

A gummy is produced by dissolving a gelling agent — typically gelatin or pectin — in a hot sugar syrup, mixing in flavor, color, and the active ingredient, then depositing the molten mass into starch molds where it cools and sets. Several steps in that process work against tight content uniformity:

• Hot-fill temperatures. Gelatin gummies are typically processed at 70–85 °C; pectin gummies often hotter still to keep the mass fluid for deposition. Many actives — vitamin C in particular degrades above roughly 70 °C — lose potency during the hot-fill window before the gummy ever leaves the kitchen.
• Mass-per-piece dosing. A gummy carries its claimed dose as a function of the weight of each finished piece. Variation in deposition weight directly becomes variation in label-claim delivery. Industry observers and contract laboratories report this as a recurring shelf-life failure mode (ConsumerLab, 2017; Nutritional Outlook, 2018).
• pH-sensitive gelling. Pectin gummies require a narrow pH band to set; "pH creep" introduced by active ingredients can prevent proper gelation, forcing manufacturers to scrap or rework batches and, in practice, encouraging conservative overages.
• Overage as a compensation strategy. Because actives degrade across an 18- to 24-month shelf life inside a sugar matrix, manufacturers add an overage at the front end so the product still meets ≥100 percent of label by expiration. USP's relevant monograph permits gummy multivitamins to contain up to 245 percent of folate and 250 percent of vitamin C and still pass, versus 150 percent for tablets and capsules (ConsumerLab, 2017). That regulatory headroom helps the shelf-life math; it also means a fresh gummy can legitimately carry more than double its label dose.

For melatonin, which is also light- and oxygen-sensitive in solution (Erland & Saxena, 2017), the combination of hot deposition and slow degradation across shelf life produces precisely the spread the JAMA analysis observed: a small number of products near label, most either well above or well below.

A polymer film is a different object. The polymer matrix (commonly hydroxypropyl methylcellulose, pullulan, or sodium alginate, depending on the formulation) is mixed with the active at relatively low temperature, cast as a thin layer onto a release liner, dried, and cut to a fixed area. Dose uniformity is largely a function of solution homogeneity and cut precision — both routinely controlled to pharmaceutical-grade tolerances (Bhati & Madan, 2013).

What the studies show — the spine

Each row deserves its own paragraph of pharmacology.

Dose accuracy. The Cohen et al. 2023 JAMA Research Letter (JAMA, 329(16):1401–1402, PMID 37097362) tested 25 melatonin gummy products purchased online after identification through the NIH Dietary Supplement Label Database. Quantification used liquid chromatography against reference standards. Of the 25, only three (12 percent) fell within ±10 percent of label; 22 (88 percent) did not. The measured range — 74 to 347 percent — spans roughly a five-fold gap between the lowest- and highest-delivering products on the same labeled dose. One product contained no detectable melatonin at all but did contain 31.3 mg of unlabeled cannabidiol (CBD). This is consistent with the earlier Erland and Saxena 2017 finding (J Clin Sleep Med, 13(2):275–281, PMID 27855744) that of 30 commercial melatonin products tested, more than 71 percent missed the label claim by more than ±10 percent and roughly a quarter contained unlabeled serotonin — a contaminant that should not be present in a melatonin product. An ODS, by contrast, is a cast and cut film; cast-film dosage forms are routinely qualified to United States Pharmacopeia general chapter <905> (Uniformity of Dosage Units), which sets an acceptance-value criterion that effectively limits between-unit deviation from label.

Heat stability. A gummy mass is held in a molten state during deposition at 70–85 °C for gelatin systems and hotter for some pectin systems (Nutritional Outlook, 2018). Vitamin C (ascorbic acid) degrades measurably above approximately 70 °C, with degradation rate increasing with temperature and humidity (Lavelli et al., 2021 — review of vitamin C stability in gummies). Melatonin is sensitive to light, pH, and temperature in aqueous solution (Daya et al., Toxicology, 2001; reviewed by Erland & Saxena, 2017). Casting a polymer film is done at much lower temperatures — frequently ambient to ~40 °C in pharmaceutical-grade processes (Bhati & Madan, Int J PharmTech Res, 2013) — which reduces thermal degradation as a manufacturing variable.

Sugar load. A typical melatonin or multivitamin gummy carries 2–4 g of added sugar per piece to mask flavor and to function as part of the matrix. The World Health Organization's 2015 strong recommendation is to limit free sugars to less than 10 percent of total energy intake, with a conditional recommendation to limit to less than 5 percent (~25 g per day for adults), specifically to reduce dental caries risk (WHO, 2015). Frequent intake matters as much as total amount: cariogenic risk tracks both the quantity and the frequency of sugar exposure, particularly when the sugar is held in the mouth in a sticky matrix that adheres to enamel (Moynihan & Kelly, J Dent Res, 2014, PMID 24323509). A nightly sleep gummy is a nightly cariogenic exposure at the worst possible moment — bedtime, after toothbrushing for many users. An ODS dissolves in seconds, contains no added sugar in MIHIYO formulations, and is not held against enamel.

Absorption route. A gummy is chewed, swallowed, and absorbed in the gut, where the active ingredient then enters the portal circulation and faces hepatic first-pass metabolism. For melatonin specifically, that first-pass step destroys most of the dose: a 2015 systematic review of 22 PK studies reported absolute oral bioavailability of 9–33 percent (Harpsøe et al., Eur J Clin Pharmacol, PMID 26008214), with extreme inter-individual variability. A polymer film designed for buccal contact dissolves against the inner cheek over roughly 60–90 seconds; a fraction of the active is absorbed across the highly vascularized, non-keratinized mucosa directly into the systemic circulation, bypassing first-pass (Patel et al., Pharmaceutics review, 2024; Bartoli et al., Drugs in R&D, 2023, PMID 37438493). The mucosal fraction is partial — the swallowed remainder still goes through the gut — but the early, first-pass-bypassing component is the part absent from any gummy route.

Safety signal in children. The CDC's June 2022 MMWR (Lelak et al., MMWR, 71(22):725–729, PMID 35653284) reported a 530 percent increase in pediatric melatonin ingestions reported to US poison centers from 2012 to 2021 — 260,435 ingestions over the decade — with five children requiring mechanical ventilation and two deaths. A follow-up MMWR Notes from the Field (Hartman et al., MMWR, 73(9):215–217, 2024) noted that flavored products including gummies and chewable tablets were involved in at least half of emergency department visits for unsupervised pediatric melatonin ingestion 2019–2022. The signal is product format. Gummies are designed to taste like candy; a young child who finds a bottle does not stop at one. An ODS in a single-dose unit pouch — bitter on the back of the tongue, single piece per pouch — does not present the same exposure pathway.

What this means for the MIHIYO Sleep-Support strip

The MIHIYO Labs Sleep-Support ODS is a cast polymer film with a low milligram melatonin dose, designed to dissolve against the buccal or sublingual mucosa over roughly 60–90 seconds. The formulation contains no added sugar and is packaged as single-dose units rather than a multi-serve gummy jar.

I want to be specific about what the cited literature does and does not cover. The Cohen 2023 JAMA analysis and the Erland & Saxena 2017 analysis tested independently purchased commercial melatonin gummies, not MIHIYO products. The MMWR pediatric data describes melatonin ingestions broadly, with format breakdowns showing gummies and chewables predominate in unsupervised pediatric exposures — that is an industry-level signal, not a MIHIYO-specific finding. The PK studies on sublingual versus oral routes were conducted on sprays and tablets, not on the MIHIYO film. What the literature supports is the design philosophy: low dose, tight uniformity, sugar-free, route that includes a mucosal-absorption fraction, and a unit-dose package that is not an attractive nuisance for children.

For the underlying pharmacology on melatonin dose-response and why low doses align with the receptor biology, see the companion article on melatonin strip dosage and the EFSA 1 mg position. For the broader mechanism comparison of sublingual versus swallowed absorption, see the foundational sublingual vs oral absorption article.

Where gummies have a real advantage

Gummies dominate the supplement aisle for a reason. The advantage is not pharmacology — it is acceptance.

For users who cannot or will not swallow a capsule — older adults with dysphagia, people with a strong gag reflex, anyone who associates "supplement" with "horse-pill" — a gummy removes the swallowing barrier entirely. Adherence to a once-daily product depends on whether the user actually takes it; a format the user enjoys gets taken. That is a real public-health gain in adherence terms (Walsh et al., Br J Clin Pharmacol, 2019, on adherence to supplement regimens).

Gummies are also simple to dose visually — one piece is one dose, no instruction needed — which matters for older adults with cognitive or vision challenges. And for ingredients that do not have meaningful first-pass loss and that survive the hot-fill window in encapsulated form, the gummy route can deliver an acceptable PK profile.

What gummies are weak at — tight dose uniformity, heat-sensitive actives, sugar-free formulation, an absorption route that includes mucosal bypass, child-resistant unit dosing — they are weak at structurally, not because of any individual manufacturer's failure. The dosage form has built-in trade-offs. A reader comparing forms should choose based on which trade-off matters most for the specific ingredient and the specific user.

The bottom line

When the question is "oral dissolving strip vs gummy" for an ingredient where dose precision, heat stability, sugar avoidance, and absorption route matter — melatonin is the textbook case — the documented data favor a cast-film ODS on four of those four dimensions. The 88 percent label-claim failure rate in the Cohen 2023 JAMA gummy analysis is not noise. It is what falls out of hot-fill, mass-per-piece, sugar-matrix manufacturing across an 18-month shelf life. A polymer film built at lower temperature, cast to uniform thickness, and dissolved in seconds against the buccal tissue is a different object solving a different problem. For palatability and swallowing comfort, gummies still win — and that is the honest place to stop pretending otherwise.

References

1. Cohen PA, Avula B, Wang YH, Katragunta K, Khan I. Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US. JAMA. 2023;329(16):1401-1402. PMID: 37097362. DOI: 10.1001/jama.2023.2296. <https://pubmed.ncbi.nlm.nih.gov/37097362/>

1. Erland LA, Saxena PK. Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content. J Clin Sleep Med. 2017;13(2):275-281. PMID: 27855744. DOI: 10.5664/jcsm.6462. <https://pubmed.ncbi.nlm.nih.gov/27855744/>

1. Lelak K, Vohra V, Neuman MI, Toce MS, Sethuraman U. Pediatric Melatonin Ingestions — United States, 2012–2021. MMWR Morb Mortal Wkly Rep. 2022;71(22):725-729. PMID: 35653284. <https://www.cdc.gov/mmwr/volumes/71/wr/mm7122a1.htm>

1. Hartman R, Sarmiento KF, Yaffee AQ, Schauben JL. Notes from the Field: Emergency Department Visits for Unsupervised Pediatric Melatonin Ingestion — United States, 2019–2022. MMWR Morb Mortal Wkly Rep. 2024;73(9):215-217. <https://www.cdc.gov/mmwr/volumes/73/wr/mm7309a5.htm>

1. Harpsøe NG, Andersen LP, Gögenur I, Rosenberg J. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol. 2015;71(8):901-909. PMID: 26008214. <https://pubmed.ncbi.nlm.nih.gov/26008214/>

1. Bartoli AN, Marchesi N, Pascale A, Quaccini A, Govoni S. Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers. Drugs in R&D. 2023. PMID: 37438493. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10439092/>

1. Moynihan PJ, Kelly SAM. Effect on caries of restricting sugars intake: systematic review to inform WHO guidelines. J Dent Res. 2014;93(1):8-18. PMID: 24323509. <https://pubmed.ncbi.nlm.nih.gov/24323509/>

1. World Health Organization. Guideline: Sugars intake for adults and children. Geneva: WHO; 2015. <https://www.who.int/publications/i/item/9789241549028>

1. Lavelli V, Sereikaite J. Kinetic study of encapsulated vitamin C degradation in pectin-based gummies and effect of process variables. LWT — Food Science and Technology. 2021. <https://www.sciencedirect.com/science/article/abs/pii/S0268005X20313886>

1. Bhati R, Nagrajan RK. A Detailed Review on Oral Mucosal Drug Delivery System. Int J Pharm Sci Res. 2013;3(3):659-681. <https://pmc.ncbi.nlm.nih.gov/articles/PMC3757902/>